Boehringer Ingelheim International Gmbh

Pharmaxis Ltd.

Ian Alexander Mcdonald

Alan Duncan Robertson

Jonathan Stuart Foot

Craig Ivan Turner

Mandar Deodhar

Alison Dorothy Findlay

Wolfgang Jarolimek

Alan Robertson

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:  The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

Substituted 3-haloallylamine inhibitors of SSAO and uses thereof

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.

Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof

Growing community of inventors

New South Wales, Australia

Ian Alexander Mcdonald